N-0385

N-0385 is an experimental small molecule TMPRSS2-inhibitor being investigated for its potential use in the prevention and treatment of COVID-19.^{[1][2][3][4][5]}

N-0385

Clinical data
Other names	Ms-QFR-Kbt
Routes of administration	Intranasal
Identifiers
IUPAC name (2S)-N-[(2S)-1-[[(2S)-1-(1,3-benzothiazol-2-yl)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-(methanesulfonamido)pentanediamide
CAS Number	2230674-01-6 Y
PubChem CID	135169285
IUPHAR/BPS	11956
Chemical and physical data
Formula	C28H36N8O6S2
Molar mass	644.77 g·mol−1
3D model (JSmol)	Interactive image
SMILES CS(=O)(=O)NC(CCC(=O)N)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(CCCN=C(N)N)C(=O)C2=NC3=CC=CC=C3S2
InChI InChI=1S/C28H36N8O6S2/c1-44(41,42)36-20(13-14-23(29)37)25(39)34-21(16-17-8-3-2-4-9-17)26(40)33-19(11-7-15-32-28(30)31)24(38)27-35-18-10-5-6-12-22(18)43-27/h2-6,8-10,12,19-21,36H,7,11,13-16H2,1H3,(H2,29,37)(H,33,40)(H,34,39)(H4,30,31,32)/t19-,20-,21-/m0/s1 Key:JTHVOFMYRRNGPA-ACRUOGEOSA-N

Mechanism of action

N-0385 is thought to have antiviral effects by targeting key proteins involved in the viral entry process, including TMPRSS2, ACE2, and DPP4. By interfering with the interactions between these proteins and the SARS-CoV-2 spike protein, N-0385 effectively blocks the virus from gaining access to host cells.^[3][4][5] Additionally, N-0385 appears to modify the immune responses and inflammatory pathways associated with the infection by regulating TLR7, NLRP3, and IL-10, potentially reducing the severity of COVID-19 symptoms and reducing tissue damage associated with the infection.^[4]